Displaying 36 (all) recruiting clinical trials.
-
PNOC029: Nivolumab and DAY101 for the treatment of newly diagnosed or recurrent craniopharyngioma in children and young adults
This study is designed for patients who have craniopharyngioma (a rare brain tumor). The usual treatment for craniopharyngioma involves surgery and radiation, which helps reduce ...
Phase
Interventional
-
AALL1821: A Phase 2 Study of Blinatumomab (NSC# 765986 IND# 125462) in Combination with Nivolumab (NSC# 748726 IND# 125462) a Checkpoint Inhibitor of PD-1 in B-ALL Patients Aged >/=1 to
The purpose of the study is to study the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell ...
Phase
Interventional
-
Pan Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS sponsored Trials Investigating Nivolumab and Other Cancer Therapies
This is a Phase 2, open-label, pan tumor trial which enrolls participants from ongoing companysponsored studies (Bristol-Myers Squibb Company [BMS] Parent Studies) that evaluated nivolumab ...Phase
Interventional
-
NCI Protocol #10612 A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma
This is a Phase 2 study comparing whether the combination of study medicines daratumumab, selinexor, bortezomib, and dexamethasone is more effective than the standard medicine ...
Phase
Interventional
-
A Phase II Study of DRP-104 a glutamine antagonist in patients with NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer and Gastroesophageal Cancer
This is a Phase 2 study testing a new medicine called DRP-104 (a glutamine antagonist) in patients with non-small cell lung cancer (NSCLC). These patients ...
Phase
Interventional
-
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients with Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer
This is a Phase 2 study testing whether a combination of TAS-102 and fruquintinib (a selective oral kinase inhibitor) is more effective and safer than ...
Phase
Interventional
